Teri L. Lawver

CIK: 0001960596

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

CLDX

Celldex Therapeutics, Inc.

Officer

ALT

Altimmune, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

CLDX
Celldex Therapeutics, Inc.
Jun 25, 2026
Award(A)
Incentive Stock Option (right to buy)
Direct
90K shares-
ALT
Altimmune, Inc.
May 1, 2026
Award(A)
Stock Options (option to buy)
Direct
48.8K shares-
CLDX
Celldex Therapeutics, Inc.
Nov 10, 2025
Award(A)
ISO (right to buy)
Direct
100K shares-
ALT
Altimmune, Inc.
Sep 25, 2025
Award(A)
Stock Options (option to buy)
Direct
48.8K shares-
ALT
Altimmune, Inc.
Feb 24, 2025
Award(A)
Stock Options (option to buy)
Direct
69.8K shares-

		Type	Shares	Price		Ownership
Jun 25, 2026	CLDX Celldex Therapeutics, Inc.	Award(A) Incentive Stock Option (right to buy)	90,000	-	-	Direct
May 1, 2026	ALT Altimmune, Inc.	Award(A) Stock Options (option to buy)	48,800	-	-	Direct
Nov 10, 2025	CLDX Celldex Therapeutics, Inc.	Award(A) ISO (right to buy)	100,000	-	-	Direct
Sep 25, 2025	ALT Altimmune, Inc.	Award(A) Stock Options (option to buy)	48,800	-	-	Direct
Feb 24, 2025	ALT Altimmune, Inc.	Award(A) Stock Options (option to buy)	69,800	-	-	Direct

1-5 of 5 transactions

About Lawver Teri L

Lawver Teri L (SEC CIK 0001960596) files insider reports with the SEC as SVP & Chief Commercial Officer of Celldex Therapeutics, Inc. (CLDX) and Director of Altimmune, Inc. (ALT).

Signal8 holds 7 ownership filings by Lawver Teri L (2 Form 3, 5 Form 4), filed between Feb 26, 2025 and Jun 29, 2026. Those filings report 5 transactions, from Feb 24, 2025 to Jun 25, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Lawver Teri L's filings is in HAMPTON, NJ.

Recent filings by Lawver Teri L

Jun 25, 2026: Grant or award of CLDX derivative securities (Form 4, code A).
May 1, 2026: Grant or award of ALT derivative securities (Form 4, code A).
Nov 10, 2025: Grant or award of CLDX derivative securities (Form 4, code A).
Sep 25, 2025: Grant or award of ALT derivative securities (Form 4, code A).
Feb 24, 2025: Grant or award of ALT derivative securities (Form 4, code A).

Other insiders filing for Celldex Therapeutics, Inc. (CLDX)

Jimenez Freddy A., SVP & GENERAL COUNSEL
Young Diane C., SVP, CHIEF MEDICAL OFFICER
Heath-Chiozzi Margo, SVP OF REGULATORY AFFAIRS
Martin Samuel Bates, SVP AND CFO
Cavanaugh Sarah, SVP OF CORP AFFAIRS & ADMIN.
Crowley Elizabeth, SR. VP & CPDO

How to read Form 4 transaction codes